Group items tagged

Mayo Clinic Hospital Medicine: Managing Complex Patients is organized by Mayo Clinic and would be held during Nov 08 - 11, 2017 at Loews Ventana Canyon Resort, Tucson, Arizona, United States Of America. The target audience for this medical event for inpatient care providers including physicians, nurse practitioners and physician assistants. Hospitalists are defined as those who spend most of their professional practice caring for hospitalized patients. This CME Conference has been approved with a maximum of 25.25 AMA PRA Category 1 Credits. Hospital Medicine is the fastest growing medical specialty and requires a diverse skill set. Hospital-based health care providers must be able to diagnose and manage a wide variety of clinical conditions, coordinate transitions of care, provide perioperative management to surgical patients and contribute to quality improvement and hospital administration. This program is specifically designed to ensure that participants augment their skill set to meet these many challenges in an effort to enhance the delivery of health care and provide better patient outcomes. Using an interactive, case-based format, key highlights from most major areas of hospital medicine will be presented. Conference Objectives are : * Classify a patient presenting with MI according to the most recent guidelines. * Select the appropriate indications for troponin testing. * Manage a patient with subsegmental pulmonary embolism. * Define sepsis according to the most recent clinical guidelines. * Select the appropriate antibiotics for a hospitalized patient with health-care associated pneumonia. * List strategies to improve the mobility of elderly patients in the hospital. * Manage a patient admitted to the hospital with diabetic ketoacidosis. * Recognize common sources of cognitive bias and heuristics to minimize their impact on patient care. * Order the appropriate tests for a hospitalized patient with a newly-diagnosed pleural effusion. * List novel the

KT3: Clinical concept and advanced whole body application is organized by Texas Children's Hospital and will be held on Jan 26, 2018 at Texas Children's Hospital, Houston, Texas, USA. This CME Conference has been approved for a maximum of 8 CCUs or 8 contact hours. Course Description : The KT3 course combines the Kinesio Taping Method foundational concepts of KT1&KT2 with advanced clinical concepts. The course provides lab time for attendees to practice their skills on the new concepts through a variety of clinical applications. The KT3 course is designed to allow the Certified Kinesio Taping Instructor (CKTI) to cater specific clinical applications to address specific professions. Upon completion of this course and prerequisite KT1&KT2 seminar, attendees will be eligible to request and take the exam to become a Certified Kinesio Taping Practitioner (CKTP). Note: Students can request to take the exam but will not be eligible to receive a CKTP certificate until they graduate. Course Objectives are : * Review the basic concepts of the Kinesio Taping Method * Explain and apply advanced concepts of the Kinesio Taping Method * Review epidermis, dermis, and fascial anatomy as it is related to Kinesio Taping * Utilize and demonstrate application skills in guided laboratory sessions * Apply the Kinesio Taping Method to stimulate epidermis, dermis, and fascial response * Apply advanced clinical taping techniques for treatment of the spine, neurological conditions, and upper/lower extremity dysfunction

Internal medicine patients are frequently prescribed potentially inappropriate medications (PIMs), but screening tools can detect clinically relevant PIMs, according to a study published online Oct. 8 in the Journal of Clinical Pharmacy and Therapeutics. Anne-Laure Blanc, Pharm.D., Ph.D., from Geneva University Hospitals in Switzerland, and colleagues compared two PIM-screening tools -- STOPP/START and PIM-Check -- in a general internal medicine ward. They also analyzed a random sample of 50 patients hospitalized in 2013, whose readmission within 30 days of discharge had been potentially preventable, and 50 sex-and age-matched patients who were not readmitted. The researchers found that across the whole ward population, PIM-Check and STOPP/START detected 1,348 and 537 PIMs, respectively, which was the equivalent of 13.5 and 5.4 PIMs per patient. PIM-Check had a substantially shorter screening time versus STOPP/START (four versus 10 minutes). Of the PIMs detected using PIM-Check and STOPP/START, the clinical pharmacist found 45 percent and 42 percent, respectively, to be clinically relevant to individual patients' cases. There were no significant differences in the rates of detected and clinically relevant PIMs between readmitted and nonreadmitted patients.

Assessment of Motor and Process Skills (AMPS) Training Workshop is organized by Texas Children's Hospital and will be held during Mar 07 - 11, 2018 at Texas, USA. This CME Conference has been approved for a maximum of 38.75 contact hours. Course Description are : The Assessment of Motor and Process Skills (AMPS) is used to measure how well a client performs familiar activities of daily living (ADL). The AMPS can be used with any client, regardless of diagnosis or age, as long as the client is at least the developmental age of 2 years and is familiar with performing some ADL tasks. There are over 125 ADL tasks included in the AMPS, from very easy self-care tasks to multi-step domestic tasks (including outdoor tasks and shopping). The AMPS measures represent how well the client performs ADL tasks, in terms of physical effort, efficiency, safety, and independence. These measures take into consideration the difficulty of the tasks the client performed and the unique scoring severity of the occupational therapist administering the AMPS. The occupational therapist can use a client's AMPS measures to plan the occupation-based and occupation-focused intervention, develop occupation-focused goals, and write occupation-focused documentation. AMPS measures can also be used as outcome measures providing evidence that a client's occupational performance changed. Using this innovative assessment tool will expand your practice by helping you deliver more occupation-centered services. Course Objectives are : Upon successful completion of this course, participants will be able to: * Understand the theoretical foundation for using the assessment tool to promote occupation centered and client-centered practice. * Administer, score, and interpret the assessment tool in a valid and reliable manner. * Use assessment results to plan occupational therapy interventions. * Interpret the results of a follow-up assessment to analyze the effectiveness of interventions. * Integr

Torticollis and Plagiocephaly: Assessment and Treatment of Infants and Children is organized by Texas Children's Hospital and will be held during Mar 16 - 18, 2018, Houston, Texas, USA. The target audience for this medical event is Physical, Occupational & Speech Therapists; Nurses, including NICU, Nurse Practitioners, Orthotists, Physician Assistants, and Physicians. This CME Conference has been approved for a maximum of 13.5 contact hours or 1.35 CEU's Credits. Course Description: This dynamic evolving course will concentrate on progressive, effective treatment schemes for infants and young children with a diagnosis of torticollis with or without plagiocephaly, including challenging cases. The course is designed to provide therapists with current research and recommendations pertaining to the implications of torticollis, sleep posture and increased use of positional devices on infant postural and motor development. Current evidence-based clinical pathways and guidelines for management of torticollis and infant head shape, including Clinical Practice Guidelines from APTA - Section on Pediatrics, will be discussed and incorporated. Red flags for related early infancy and preschool diagnoses will be appraised. Current functional, clinically oriented evaluation and evidence based treatment strategies for infants and young children that can be integrated into routines and play will be provided. Diagnostic procedures and surgical intervention will be reviewed. Recommendations for follow-up and secondary specialist consultations will be presented. Emphasis on home exercise programs and effective strategies to team with parents will be explored.

Water - Based Interventions for the Pediatric Therapies is organized by Texas Children's Hospital and will be held during Mar 03 - 04, 2018 at Blue Lagune Therapy - Aquatic & Land Physical Therapy, Katy, Texas, United States of America. This CME Conference has been approved for a maximum of 16 CCUs Credits. Course Description: This Course is designed to rapidly introduce pediatric therapists to motor, sensory and play-based interventions in water. Participants will create a series of aquatic therapeutic movements, tasks, or exercises designed to alleviate the most common problems associated with the pediatric population and then adapte these ideas to novel situations. Participants will briefly examine research which supports aquatic therapy for the child and explore contraindications, including prevailing precaution myths. Course Objectives : * Discriminate between aquatic precautions and contraindications specific to the pediatric client. Defend any choice, on a case-by-case basis, to label a condition as a precaution and not as a contraindication. * Explain why aquatic therapy may be the treatment of choice if (a) the patient has poor head or trunk righting/control, (b) the patient has spasticity, (c) the patient has difficulty with transitional movements; (d) the patient has poor sensory processing; (e) the patient has speech/language deficits; or (f) research supports its use. * Design a sample aquatic treatment session demonstrating 2 ways to divide labor between PT, OT and SLP. Compare and contrast 5 ways that the goals of 3 different disciplines should differ. Recommend 3 ways to co-treat in water and be reimbursed for the services provided. * Originate, integrate, and combine ideas into a plan to implement augmentative communication in the therapy pool setting. Incorporate low-tech augmentative communication methods during labs to improve communication. * Gather and organize the latest aquatic research to bolster the case for treatment and to aid in t

Pediatric Gait Analysis And Orthotic Management: A Segmental Kinematic Approach to Rehabilitation is organized by Texas Children's Hospital and will be held during Feb 18 - 20, 2018 at Conroe, Texas, USA. This CME Conference has been approved for a maximum of 18.75 Credits. Course Description: The course is intended primarily for paediatric physiotherapists, orthotists and other professionals working in the field of paediatric gait rehabilitation. It is also highly relevant to physiotherapists, orthotists and others working in the fields of adult neurology and adult learning disability. The course explores a fresh approach to the observation and analysis of normal walking and standing, and the classification and management of gait disorders. The biomechanics of normal walking and standing, and the pathological gaits of disabling conditions will be extensively reviewed, with particular reference to orthotic management. Pre-gait analysis and orthotic management assessment will be demonstrated. The emphasis of patient cases will focus on cerebral palsy, myelomeningocoele and other neurological conditions. Participants will gain knowledge of the aims of orthotic management and how to achieve them through: the biomechanics of ankle-foot orthoses, the influence of footwear, varieties of AFO Footwear Combination design, tuning AFO Footwear Combinations to optimise gait and extensive video examples. In addition live patient demonstrations will help participants refine their clinical decision making skills involved in gait analysis and orthotic design. Each delegate will receive an illustrated course manual, which includes extensive reference lists and directions for further reading, and a CD containing additional information and proformas.

Management of type 2 diabetes should include shared decision making, and patients should be offered individualized diabetes self-management education and glycemic management plans, according to a summary of a clinical practice guideline published online Oct. 23 in the Annals of Internal Medicine. Paul R. Conlin, M.D., from the VA Boston Healthcare System in West Roxbury, Massachusetts, and colleagues convened a joint U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) Evidence-Based Practice Work Group to develop a guideline for management of type 2 diabetes mellitus. The authors provided updates on management within seven areas: patient-centered care and shared decision making, glycemic biomarkers, target ranges of hemoglobin A1c (HbA1c), individualized treatment plans, pharmacologic treatment in the outpatient setting, glucose targets for critically ill patients, and treatment for patients in the hospital. Patients should be offered individualized diabetes self-management education, as well as individualized glycemic management plans and target ranges for HbA1c. "In summary, the VA/DoD CPG [clinical practice guideline] attempts to convey to clinicians, policymakers, and patients the rationale for personalizing treatment on the basis of results from major trials, limitations of the HbA1c test, and evaluation of patient risk for adverse drug events. Conveying complex information in an understandable manner to individual patients and families through a formal process of shared decision making is thus foundational to setting and revising goals that are meaningful, safe, and achievable in everyday clinical practice," the authors write.

For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according to a study published online Oct. 11 in the New England Journal of Medicine. Edward Gane, M.D., from Auckland City Hospital in New Zealand, and colleagues conducted a multicenter trial to examine the efficacy and safety of combination treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults with HCV infection and compensated liver disease with severe renal impairment, dependence on dialysis, or both. Participants had stage 4 or 5 chronic kidney disease. One hundred four patients were enrolled in the trial. The researchers found that the sustained virologic response rate was 98 percent. During treatment, none of the patients had virologic failure, and none had a virologic relapse after the end of treatment. Pruritus, fatigue, and nausea were reported in at least 10 percent of the patients. Twenty-four percent of the patients reported serious adverse events. Because of adverse events, four patients discontinued the trial treatment prematurely; three of these had sustained virologic response

As a cardiologist, your expertise includes the diagnosis, treatment and prevention of heart and blood vessel diseases. Patients of all ages may be sent to you, or perhaps you have chosen to specialize in an area like geriatric or pediatric cardiology. And even though you have completed an extensive amount of internal medicine and cardiology education to-date, on-going training requirements must still be fulfilled. We can help you find continuing medical education (CME) courses that are just as specialized as your skill set. Our database of cardiology medical conferences can help you find CME opportunities that meet your needs. In addition to general cardiovascular medicine events, we feature conferences dedicated to specific topics like heart rhythm, echocardiography, hypertension and more. Register for events hosted by leading hospitals in cardiology such as the Cleveland Clinic and the Mayo Clinic. Are you ready to attend your next cardiology conference? To get started, review our list of upcoming Fellows courses, annual updates, case reviews, forums and more. And for additional events, we recommend checking out our database of Interventional Cardiology and Vascular Disease conferences.

American College of Emergency Physicians (ACEP) Scientific Assembly is organized by American College of Emergency Physicians (ACEP) and would be held during Oct 29 - Nov 01, 2017 at Walter E. Washington Convention Center, Washington, Dist of Col, United States of America. The target audience for this medical event for Emergency Physicians, Emergency Nurses, Nurse Practitioners, Residents and Fellows, Medical Students. This cme conference has been approved with a maximum of 29 AMA PRA Category 1 Credits. This Course will consist of clinical, as well as essential management and risk management tools to aid in your day-to-day practice. With educational courses, skills labs and workshops - ACEP17 is the best source for your emergency medicine education needs! Conference Objectives are : * Abdominal Disorders * Airway, Anesthesia, Analgesia * Cardiovascular * Career Advancement Through Teaching * Critical Care * Critical ED Management * Dematologic Disorders * Emergency Imaging * Head & Neck Disorders * Health Policy * Hematologic Disorders * Infectious Disease * Knowledge Translation * Maintenance of Certification * Metabolic and Endocrine Disorders * Neurology * New Technology * Orthopedics and Sports Medicine * Pediatric Disorders * Prehospital / Disaster Medicine * Professional Skills * Pulmonary Disorders * Risk Management / ED and Law * Toxicology / Environmental * Trauma * Urologic and OB/GYN ACEP17 is the must attend event for anyone engaged in the practice of emergency medicine, including : * Emergency Physicians * Nurse Practitioners * Residents * Medical Students * Physician Assistant * Emergency Department Medical Directors * Hospital Administrators * EMTs/Paramedics

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.

We know that as a doctor of internal medicine, you are responsible for the prevention, diagnosis and treatment of a wide variety of conditions in your adolescent, adult and geriatric patients. You may practice in an office, an outpatient center, a hospital or even in multiple settings. Your required healthcare expertise is wide-ranging, and as such, reflects the need for CME options that are just as comprehensive. Our medical conference database can help you find a variety of CME opportunities related to the practice of general medicine. Register for conferences hosted by leading internal medicine organizations such as the Mayo Clinic, UCSF School of Medicine and Harvard Medical School. In addition to conferences that cover broad primary care topics, there are numerous events that integrate sub-specialties like clinical endocrinology, orthopedics, cardio/pulmonary medicine and more. To make your search more specific, filter events by location, amount of CME credits offered or even by keyword. If you are ready to expand your knowledge of the health issues affecting your patients, start reviewing our list of upcoming exam board reviews, workshops, annual updates and other types of internal medicine conferences today. And for additional events, we recommend searching our database of Family Medicine and Hospital Medicine conferences

Immediate access to opioid agonist treatment (OAT) for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care, according to a study published online Nov. 21 in the Annals of Internal Medicine. Emanuel Krebs, from St. Paul's Hospital in Vancouver, Canada, and colleagues sought to determine the cost-effectiveness of OAT versus observed standard of care for patients presenting with opioid use disorder. Population-level administrative databases capturing treatment and criminal justice records for California were linked (2006 to 2010). Immediate access to OAT for all treatment recipients was found by the researchers to cost less (by $78,257), with patients accumulating more quality-adjusted life-years (by 0.42) versus the observed standard of care. Imagining a hypothetical scenario where all Californians starting treatment of opioid use disorder in 2014 had immediate access to OAT, the team found that total lifetime savings for this cohort could be as high as $3.8 billion.

More than 78 percent of health care personnel (HCP) and 53.6 percent of pregnant women received influenza vaccination during the 2016-2017 influenza season, according to two studies published in the Sept. 29 issue of Morbidity and Mortality Weekly Report. Carla L. Black, Ph.D., from the U.S. Centers for Disease Control and Prevention (CDC), and colleagues surveyed 2,438 HCP to estimate influenza vaccination coverage. The researchers found that during the 2016-2017 season, 78.6 percent of survey respondents reported receiving vaccination, similar to reported coverage in the previous three seasons. Coverage was highest for those working in hospitals compared with those working in ambulatory or long-term-care settings (92.3 versus 76.1 and 68 percent) and for those who were required by their employer to be vaccinated (96.7 percent), as in previous seasons. Helen Ding, M.D., from the CDC, and colleagues surveyed 1,893 women pregnant at any time during October 2016 to January 2017. The researchers found that 53.6 percent of respondents reported having received influenza vaccination before or during pregnancy (16.2 and 37.4 percent, respectively); this was similar to coverage during the previous four influenza seasons. Overall, 67.3, 11.9, and 20.7 percent of women reported receiving a provider offer for influenza vaccination, receiving a recommendation but no offer, and receiving no recommendation, respectively, similar to the previous influenza season; influenza vaccination coverage was 70.5, 43.7, and 14.8 percent, respectively, among these women.

Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism. Melanie J. Davies, M.D., from the University Hospitals of Leicester NHS Trust in the United Kingdom, and colleagues conducted post hoc analysis using data from 5,908 participants in five randomized, double-blind, placebo-controlled clinical trials of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management, in order to assess cardiovascular risk. The researchers found that with liraglutide (3.0 mg), eight participants had positively adjudicated cardiovascular events (1.54 events/1,000 person-years), compared to 10 participants in the comparators group (3.65 events/1000 person-years). Compared to the non-liraglutide group, the hazard ratio for 3.0 mg liraglutide treatment was 0.42 (95 percent confidence interval, 0.17 to 1.08).

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C. Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up. The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.